Compare KD & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | XENE |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United States | Canada |
| Employees | 80000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2021 | 2014 |
| Metric | KD | XENE |
|---|---|---|
| Price | $13.52 | $54.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $25.92 | ★ $68.55 |
| AVG Volume (30 Days) | ★ 3.4M | 781.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.95 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $15,057,000,000.00 | $311,000.00 |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $0.08 | $2,496.48 |
| P/E Ratio | $17.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.10 | $28.19 |
| 52 Week High | $43.74 | $62.91 |
| Indicator | KD | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 49.47 | 45.16 |
| Support Level | $12.03 | $52.55 |
| Resistance Level | $13.81 | $56.66 |
| Average True Range (ATR) | 0.55 | 1.72 |
| MACD | 0.04 | -0.80 |
| Stochastic Oscillator | 51.78 | 19.06 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.